Alterations at the Cross-Bridge Level Are Associated with a Paradoxical Gain of Muscle Function In Vivo in a Mouse Model of Nemaline Myopathy
Open Access
- 30 September 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (9) , e109066
Abstract
Nemaline myopathy is the most common disease entity among non-dystrophic skeletal muscle congenital diseases. The first disease causing mutation (Met9Arg) was identified in the gene encoding α-tropomyosinslow gene (TPM3). Considering the conflicting findings of the previous studies on the transgenic (Tg) mice carrying the TPM3Met9Arg mutation, we investigated carefully the effect of the Met9Arg mutation in 8–9 month-old Tg(TPM3)Met9Arg mice on muscle function using a multiscale methodological approach including skinned muscle fibers analysis and in vivo investigations by magnetic resonance imaging and 31-phosphorus magnetic resonance spectroscopy. While in vitro maximal force production was reduced in Tg(TPM3)Met9Arg mice as compared to controls, in vivo measurements revealed an improved mechanical performance in the transgenic mice as compared to the former. The reduced in vitro muscle force might be related to alterations occuring at the cross-bridges level with muscle-specific underlying mechanisms. In vivo muscle improvement was not associated with any changes in either muscle volume or energy metabolism. Our findings indicate that TPM3(Met9Arg) mutation leads to a mild muscle weakness in vitro related to an alteration at the cross-bridges level and a paradoxical gain of muscle function in vivo. These results clearly point out that in vitro alterations are muscle-dependent and do not necessarily translate into similar changes in vivo.Keywords
This publication has 50 references indexed in Scilit:
- Perturbed Length-Dependent Activation in Human Hypertrophic Cardiomyopathy With Missense Sarcomeric Gene MutationsCirculation Research, 2013
- Combined MRI and 31P-MRS Investigations of the ACTA1(H40Y) Mouse Model of Nemaline Myopathy Show Impaired Muscle Function and Altered Energy MetabolismPLOS ONE, 2013
- Clinical utility gene card for: Nemaline myopathyEuropean Journal of Human Genetics, 2012
- Changes in cross-bridge cycling underlie muscle weakness in patients with tropomyosin 3-based myopathyHuman Molecular Genetics, 2011
- Nebulin Alters Cross-bridge Cycling Kinetics and Increases Thin Filament ActivationJournal of Biological Chemistry, 2009
- Nebulin plays a direct role in promoting strong actin‐myosin interactionsThe FASEB Journal, 2009
- Disease Severity and Thin Filament Regulation in M9RTPM3Nemaline MyopathyJournal of Neuropathology & Experimental Neurology, 2008
- Sarcoplasmic reticulum calcium uptake and speed of relaxation are depressed in nebulin‐free skeletal muscleThe FASEB Journal, 2008
- Skeletal muscle repair in a mouse model of nemaline myopathyHuman Molecular Genetics, 2006
- Nebulin-deficient mice exhibit shorter thin filament lengths and reduced contractile function in skeletal muscleJournal of Cell Biology, 2006